Compare GDOT & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | ODTX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.0M | 875.1M |
| IPO Year | 2010 | 2025 |
| Metric | GDOT | ODTX |
|---|---|---|
| Price | $13.53 | $20.78 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 359.2K | 177.5K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $2,080,491,000.00 | N/A |
| Revenue This Year | $11.07 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $40.76 | ★ N/A |
| Revenue Growth | ★ 20.69 | N/A |
| 52 Week Low | $10.10 | $15.10 |
| 52 Week High | $15.41 | $23.03 |
| Indicator | GDOT | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 54.42 |
| Support Level | $12.77 | $15.10 |
| Resistance Level | $13.73 | N/A |
| Average True Range (ATR) | 0.32 | 1.70 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 91.83 | 49.67 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.